Author

S. Mouche

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Larrue· 3 shared J. Tamburini· 3 shared C. Recher· 2 shared F. Vergez· 2 shared J.-E. Sarry· 2 shared A. Conway· 1 shared A. Letai· 1 shared A. Robichaud· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Larrue

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells

C. Larrue, S. Mouche, P. Angelino, M. Sajot, R. Birsen, F. Vergez, C. Recher, V. Mansat-De Mas, Q. Gu, J. Xu, P. Tsantoulis, J.-E. Sarry, J. Tamburini

The paper identifies ferritinophagy as a therapeutic target in quiescent leukemic stem cells, showing that inhibiting NCOA4 reduces leukemia.

bioRxiv · Dec 18, 2023 · PreprintCancer Biology

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML

S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier

This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.

bioRxiv · Dec 28, 2020Cancer Biology

Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells

C. Larrue, N. Guiraud, P.-L. Mouchel, M. Dubois, T. Farge, M. Gotanegre, C. Bosc, E. Saland, M.-L. Travers-Nicolau, M. Sabatier, N. Serhan, A. Sahal, E. Boet, S. Mouche, Q. Heydt, , J.-E. Sarry

The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.

bioRxiv · Aug 17, 2020Cancer Biology